Neuroprotective compounds and innovative therapeutic strategies for Parkinson’s disease: Experimental and clinical studies

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Identifying new therapeutic strategies capable of modifying the course of Parkinson’s disease (PD) is currently one of the major goals for the researchers of this field. Various mechanistic definitions have been proposed to describe the hypothetical ability of a therapeutic intervention to prevent, block or reverse the neurodegenerative process underlying PD. The general term “neuroprotection” has been related to the capacity of interfering with the ongoing process of neuronal cell death, in order to slow or halt disease progression, while a term such as “neurorestoration” would apply to any intervention capable of increasing the number of surviving dopaminergic neurons. Although none of the therapeutic approaches tested in PD patients has so far shown the ability to stop or reverse disease progression, a certain degree of neuroprotection can be achieved with compounds that are already available in the pharmacological armamentarium of the neurologist. Treatment with dopamine agonists or MAO-B inhibitors, particularly when started in the very early phases of the disease, may play disease-modifying effects and even L-DOPA, at low doses, may be slightly neuroprotective. For a true neurorestorative intervention, promising perspectives are being provided by neurotrophic factors and stem cells, which, however, still need to unveil their full potential.

Original languageEnglish
Pages (from-to)1-15
Number of pages15
JournalOpen Access Journal of Clinical Trials
Volume1
Publication statusPublished - Sep 29 2009

Fingerprint

Parkinsonian Disorders
Parkinson Disease
Disease Progression
Monoamine Oxidase Inhibitors
Dopaminergic Neurons
Dopamine Agonists
Monoamine Oxidase
Nerve Growth Factors
Therapeutics
Cell Death
Stem Cells
Research Personnel
Pharmacology
Clinical Studies
Neuroprotection

Keywords

  • Dopamine agonists
  • L-DOPA
  • MAO-B inhibitors
  • Stem cells
  • Trophic factors

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Pharmacology (medical)

Cite this

@article{223025ba62c7481b957cc731a5aea887,
title = "Neuroprotective compounds and innovative therapeutic strategies for Parkinson’s disease: Experimental and clinical studies",
abstract = "Identifying new therapeutic strategies capable of modifying the course of Parkinson’s disease (PD) is currently one of the major goals for the researchers of this field. Various mechanistic definitions have been proposed to describe the hypothetical ability of a therapeutic intervention to prevent, block or reverse the neurodegenerative process underlying PD. The general term “neuroprotection” has been related to the capacity of interfering with the ongoing process of neuronal cell death, in order to slow or halt disease progression, while a term such as “neurorestoration” would apply to any intervention capable of increasing the number of surviving dopaminergic neurons. Although none of the therapeutic approaches tested in PD patients has so far shown the ability to stop or reverse disease progression, a certain degree of neuroprotection can be achieved with compounds that are already available in the pharmacological armamentarium of the neurologist. Treatment with dopamine agonists or MAO-B inhibitors, particularly when started in the very early phases of the disease, may play disease-modifying effects and even L-DOPA, at low doses, may be slightly neuroprotective. For a true neurorestorative intervention, promising perspectives are being provided by neurotrophic factors and stem cells, which, however, still need to unveil their full potential.",
keywords = "Dopamine agonists, L-DOPA, MAO-B inhibitors, Stem cells, Trophic factors",
author = "Fabio Blandini",
year = "2009",
month = "9",
day = "29",
language = "English",
volume = "1",
pages = "1--15",
journal = "Open Access Journal of Clinical Trials",
issn = "1179-1519",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Neuroprotective compounds and innovative therapeutic strategies for Parkinson’s disease

T2 - Experimental and clinical studies

AU - Blandini, Fabio

PY - 2009/9/29

Y1 - 2009/9/29

N2 - Identifying new therapeutic strategies capable of modifying the course of Parkinson’s disease (PD) is currently one of the major goals for the researchers of this field. Various mechanistic definitions have been proposed to describe the hypothetical ability of a therapeutic intervention to prevent, block or reverse the neurodegenerative process underlying PD. The general term “neuroprotection” has been related to the capacity of interfering with the ongoing process of neuronal cell death, in order to slow or halt disease progression, while a term such as “neurorestoration” would apply to any intervention capable of increasing the number of surviving dopaminergic neurons. Although none of the therapeutic approaches tested in PD patients has so far shown the ability to stop or reverse disease progression, a certain degree of neuroprotection can be achieved with compounds that are already available in the pharmacological armamentarium of the neurologist. Treatment with dopamine agonists or MAO-B inhibitors, particularly when started in the very early phases of the disease, may play disease-modifying effects and even L-DOPA, at low doses, may be slightly neuroprotective. For a true neurorestorative intervention, promising perspectives are being provided by neurotrophic factors and stem cells, which, however, still need to unveil their full potential.

AB - Identifying new therapeutic strategies capable of modifying the course of Parkinson’s disease (PD) is currently one of the major goals for the researchers of this field. Various mechanistic definitions have been proposed to describe the hypothetical ability of a therapeutic intervention to prevent, block or reverse the neurodegenerative process underlying PD. The general term “neuroprotection” has been related to the capacity of interfering with the ongoing process of neuronal cell death, in order to slow or halt disease progression, while a term such as “neurorestoration” would apply to any intervention capable of increasing the number of surviving dopaminergic neurons. Although none of the therapeutic approaches tested in PD patients has so far shown the ability to stop or reverse disease progression, a certain degree of neuroprotection can be achieved with compounds that are already available in the pharmacological armamentarium of the neurologist. Treatment with dopamine agonists or MAO-B inhibitors, particularly when started in the very early phases of the disease, may play disease-modifying effects and even L-DOPA, at low doses, may be slightly neuroprotective. For a true neurorestorative intervention, promising perspectives are being provided by neurotrophic factors and stem cells, which, however, still need to unveil their full potential.

KW - Dopamine agonists

KW - L-DOPA

KW - MAO-B inhibitors

KW - Stem cells

KW - Trophic factors

UR - http://www.scopus.com/inward/record.url?scp=84944749674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944749674&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84944749674

VL - 1

SP - 1

EP - 15

JO - Open Access Journal of Clinical Trials

JF - Open Access Journal of Clinical Trials

SN - 1179-1519

ER -